First human doses of experimental drug ARO-033 begin safety testing
NCT ID NCT07662096
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is the first time the experimental drug ARO-033 is being given to humans. Its main goal is to check the safety and tolerability of single and multiple doses in healthy adult volunteers. Researchers will also measure how the drug moves through the body. This is an early step to see if ARO-033 is safe enough for future studies in people with specific diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARO-033
What this could lead to
If safe and well-tolerated, this could pave the way for future studies of ARO-033 in specific diseases.
What could go wrong
This is a very early, small study in healthy people, not patients. It only tests safety and drug levels, not whether the drug works for any condition. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••